Table 3 Reduction (improvement) from Baseline in WOMAC Pain. N (%)
From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis
| Â | Â | 0.03 mg (N = 7) | 0.1 mg (N = 6) | 0.3 mg (N = 6) | 1 mg (N = 6) | All (N = 25) | Placebo (N = 8) |
|---|---|---|---|---|---|---|---|
Mean Baseline Score (0-20) | 7.57 | 10.5 | 8.2 | 8.33 | 8.6 | 8.6 | |
Week 4 | 20% Reduction | 3 (42.9%) | 3 (50.0%) | 2 (33.3%) | 5 (83.3%) | 13 (52%) | 1 (12.5%) |
Week 8 | 20% Reduction | 3 (42.9%) | 5 (83.3%) | 3 (50.0%) | 5 (83.3%) | 16 (64%) | 3 (37.5%) |
Week 12 | 20% Reduction | 4 (57.1%) | 5 (83.3%) | 3(50.0%) | 1 (16.7%) | 13 (52%) | 4 (50.0%) |
Week 24 | 20% Reduction | 4 (57.1%) | 5 (83.3%) | 5 (83.3%) | 1 (16.7%) | 15 (60%) | 4 (50.0%) |
Week 4 | 50% Reduction | 3 (42.9%) | 2 (33.3%) | 2 (33.3%) | 3 (50.0%) | 10 (40%) | 0 (0.0%) |
Week 8 | 50% Reduction | 1 (14.3%) | 3 (50.0%) | 3 (50.0%) | 4 (66.7%) | 11 (44%) | 0 (0.0%) |
Week 12 | 50% Reduction | 0 (0.0%) | 3 (50.0%) | 2 (33.3%) | 1 (16.7%) | 6 (24%) | 1(12.5%) |
Week 24 | 50% Reduction | 0 (0.0%) | 5 (83.3%) | 3 (50.0%) | 1 (16.7%) | 9 (36%) | 0 (0.0%) |
Week 4 | 70% Reduction | 1 (14.3%) | 1 (16.7%) | 2 (33.3%) | 1 (16.7%) | 5 (20%) | 0 (0.0%) |
Week 8 | 70% Reduction | 1 (14.3%) | 1 (16.7%) | 2 (33.3%) | 1 (16.7%) | 5 (20%) | 0 (0.0%) |
Week 12 | 70% Reduction | 0 (0.0%) | 2 (33.3%) | 2 (33.3%) | 0 (0.0%) | 4 (16%) | 0 (0.0%) |
Week 24 | 70% Reduction | 0 (0.0%) | 3 (50.0%) | 3 (50.0%) | 0 (0.0%) | 6 (24%) | 0 (0.0%) |